Status:
COMPLETED
Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy
Lead Sponsor:
Tameside Hospital NHS Foundation Trust
Conditions:
Diabetic Neuropathy
Eligibility:
All Genders
18-70 years
Brief Summary
Diabetes mellitus can result in damage to the nerves supplying the feet. Various tests can be used to assess nerve damage but no tests so far have been used to assess loss of sweating which can lead t...
Detailed Description
With increasing nervous dysfunction, the function of the sweat glands in the feet also diminishes and can cease completely. As a result the skin becomes brittle and dry, making it more susceptible to ...
Eligibility Criteria
Inclusion
- Type 1 or type 2 diabetes
- Age 18-70 years
- Presence of painless neuropathy
- Presence of painful neuropathy
- Presence of Charcot foot
Exclusion
- Patients with allergy to any metal
- Peripheral vascular disease (defined as the absence of two or more foot pulses and an ankle brachial index of \< 0.8)
- Renal failure (serum creatinine \> 130 micromol/l)
- Foot ulceration or cellulitis or osteomyelitis
- Patients taking drugs that affect sweating (corticosteroids, antihistamines, psychoactive drugs)
- Chronic alcohol abuse
- B12 deficiency (presence of anaemia, raised mean corpuscular volume, past history of abnormal B12 levels, treatment with B12)
- Patients with any skin conditions affecting their feet(neurodermatitis, psoriasis, scleroderma, Raynaud syndrome, hyperhydrosis, acrocyanosis)
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00895440
Start Date
July 1 2009
End Date
June 1 2013
Last Update
November 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tameside General Hospital
Ashton-under-Lyne, Lancashire, United Kingdom, OL69RW